Does BICALUTAMIDE Cause Second primary malignancy? 5 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 5 reports of Second primary malignancy have been filed in association with BICALUTAMIDE (Bicalutamide). This represents 0.1% of all adverse event reports for BICALUTAMIDE.
5
Reports of Second primary malignancy with BICALUTAMIDE
0.1%
of all BICALUTAMIDE reports
1
Deaths
3
Hospitalizations
How Dangerous Is Second primary malignancy From BICALUTAMIDE?
Of the 5 reports, 1 (20.0%) resulted in death, 3 (60.0%) required hospitalization.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for BICALUTAMIDE. However, 5 reports have been filed with the FAERS database.
What Other Side Effects Does BICALUTAMIDE Cause?
Malignant neoplasm progression (352)
Prostatic specific antigen increased (322)
Drug ineffective (268)
Fatigue (258)
Prostate cancer (258)
Asthenia (223)
Hot flush (219)
Off label use (171)
Disease progression (169)
Anaemia (164)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which BICALUTAMIDE Alternatives Have Lower Second primary malignancy Risk?
BICALUTAMIDE vs BICTEGRAVIR
BICALUTAMIDE vs BICTEGRAVIR\EMTRICITABINE\TENOFOVIR ALAFENAMIDE
BICALUTAMIDE vs BIFIDOBACTERIUM LONGUM
BICALUTAMIDE vs BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS
BICALUTAMIDE vs BILASTINE